The estimated Net Worth of Richard Chen is at least $6.98 million dollars as of 30 July 2024. Dr Chen owns over 524 units of Personalis Inc stock worth over $757,001 and over the last 5 years he sold PSNL stock worth over $5,585,518. In addition, he makes $638,500 as Sr. VP of R&D and Chief Medical Officer at Personalis Inc.
Dr has made over 50 trades of the Personalis Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 524 units of PSNL stock worth $1,556 on 30 July 2024.
The largest trade he's ever made was exercising 101,000 units of Personalis Inc stock on 25 February 2020 worth over $600,950. On average, Dr trades about 7,203 units every 28 days since 2019. As of 30 July 2024 he still owns at least 127,227 units of Personalis Inc stock.
You can see the complete history of Dr Chen stock trades at the bottom of the page.
Dr. Richard Chen M.D., M.S., MS is the Sr. VP of R&D and Chief Medical Officer at Personalis Inc.
As the Sr. VP of R&D and Chief Medical Officer of Personalis Inc, the total compensation of Dr MS at Personalis Inc is $638,500. There are 5 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.
Dr MS is 50, he's been the Sr. VP of R&D and Chief Medical Officer of Personalis Inc since . There are 10 older and 6 younger executives at Personalis Inc. The oldest executive at Personalis Inc is A. Blaine Bowman, 73, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci et Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: